Safety and efficacy of single-dose fluconazole compared with a 7-day regimen of itraconazole in the treatment of AIDS-related oropharyngeal candidiasis

Journal of International Medical Research

Volumn 26, Issue 3, 1998, Pages 159-170

  De Wit, S ^a   O'Doherty, E ^a   De Vroey, C ^b   Clumeck, N ^a  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

Acquired immune deficiency syndrome (AIDS); Antifungal drugs; Fluconazole; Human immunodeficiency virus (HIV); Itraconazole; Oropharyngeal candidiasis

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CANDIDIASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INTERACTION; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MALE; ORAL DRUG ADMINISTRATION; OROPHARYNX; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; TREATMENT FAILURE;

EID: 0031903489     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/030006059802600307     Document Type: Article

References (27)

1. Hessel NA, Buchbinder SP: Predictors of HIV disease progression in the era of prophylactic therapies. In: AIDS Clinical Review (Volberding P, Jacobson MA, eds). New York: Dekker, 1992; pp 25-40.
2. Samaranayake LP, Holmstrup P: Oral candidiasis and human immunodeficiency virus infection. J Oral Pathol Med 1989; 18: 554-564.
3. Anon: Oral candidosis in HIV infection [editorial]. Lancet 1989; 1: 1491-1492.
4. Marchisio P, Principi N: Treatment of oropharyngeal candidiasis in HIV-infected children with oral fluconazole. Eur J Clin Microbiol Infect Dis 1994; 13: 338-340.
5. Leen CLS, Dunbar EM, Ellis ME, Mandel BK: Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled study. J Infect 1990; 21: 55-60.
6. De Wit S, Urbain D, Rahir F, et al: Efficacy of oral fluconazole in the treatment of AIDS associated oesophageal candidiasis. Eur J Clin Microbiol Infect Dis 1991; 10: 1-3.
7. Dupont B, Drouhet E: Fluconazole in the management of oropharyngeal candidosis in a predominantly HIV antibody-positive group of patients. J Med Vet Mycol 1988; 26: 67-71.
8. De Wit S, Goosens H, Weerts D, Clumeck N: Comparison of fluconazolo and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet 1989; 1: 746-748.
9. Meunier F, Aoun M, Gerard M: Therapy for oropharyngeal candidiasis in the immunocompromised host: a randomised double-blind study of fluconazole vs ketoconazole. Rev Infect Dis 1990; 12 (suppl 3): S365-S368.
10. Blatchford NR: Treatment of oral candidosis with itraconazole: a review. J Am Acad Dermatol 1990; 23: 565-567.
11. Phillips P, Zemcov J, Mahmood W, et al: Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility. AIDS 1996; 10: 1369-1376.
12. Chave JP, Cajot A, Bille J, Glauser MP: Single-dose therapy for oral candidiasis with fluconazole in HIV-infected adults: a pilot study. J Infect Dis 1989; 159: 806-807.
13. De Wit S, Clumeck N: Therapeutic approach to mycotic infections in AIDS patients. Rev Med Microbiol 1991; 2: 57-60.
14. De Wit S, Goosens H, Clumeck N: Single-dose versus 7 days of fluconazole treatment for oral candidiasis in human immunodeficiency virus-infected patients: a prospective randomised pilot study. J Infect Dis 1993; 168: 1332-1333.
15. Zimmerman T, Yeates RA, Laufen H, et al: Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol 1994; 46: 147-150.
16. Garcia-Hermosa D, Dromer F, Improvosi L, et al: Fluconazole concentrations in saliva from AIDS patients with oropharyngeal candidosis refractory to treatment with fluconazole. Antimicrob Agents Chemother 1995; 39: 656-660.
17. Just-Nubling G, Gentschew G, Dohle M, et al: Fluconazole in the treatment of oropharyngeal candidiasis in HIV-positive patients. Mycoses 1990; 33: 435-440.
18. Dios PD, Alvarez JA, Feijoo JF, Ferreiro MC: Fluconazole response patterns in HIV-infected patients with oropharyngeal candidiasis. Oral Surg Oral Med Oral Pathol 1995; 79: 170-174.
19. Heykants J, Van Peer A, Van de Velde V, et al: The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1987; 32 (suppl 1): 67-87.
20. Drayton J, Dickinson G, Rinaldi MG: Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole. Clin Infect Dis 1994; 18: 266.
21. May DB, Drew RH, Yedinak KC, Bartlett JA: Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers. Pharmacotherapy 1994; 14: 509-513.
22. Brodell RT, Elewski BE: Clinical pearl: systemic antifungal drugs and drug interactions. J Am Acad Dermatol 1995; 33: 259-260.
23. De Wit S, Debier M, De Smet M, et al: Effect of fluconazole on indinavir pharmacokinetics in human immunodeficiency virus infected patients. Antimicrob Agents and Chemother 1998; 42(2): 223-227.
24. Barone JA, Koh JG, Bierman RH, et al: Food interaction and steady state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 1993; 37: 778-784.
25. Lim SG, Sawyerr AM, Hudson M, et al: Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment Pharmacol Ther 1993; 7: 317-321.
26. Haria M, Bryson HM, Goa KL: Itraconazole: a reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 1996; 51: 585-620.
27. Smith D, Van de Velde V, Woestenborghs R, Gazzard BG: The pharmacokinetics of oral itraconazole in AIDS patients. J Pharm Pharmacol 1992; 44: 618-619.